Article info
Commentary
NEMO—CXCL12/CXCR4 axis: a novel vantage point for antifibrotic therapies in chronic pancreatitis?
- Correspondence to Professor Volker Ellenrieder, Department of Gastroenterology and GI Oncology, University Medical Center Goettingen, Robert Koch Str. 40, Goettingen 37075, Germany; volker.ellenrieder{at}med.uni-goettingen.de
Citation
NEMO—CXCL12/CXCR4 axis: a novel vantage point for antifibrotic therapies in chronic pancreatitis?
Publication history
- Received August 12, 2016
- Accepted August 15, 2016
- First published September 2, 2016.
Online issue publication
January 06, 2017
Article Versions
- Previous version (2 September 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/